OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like g...OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like growth factor-binding protein-3(IGFBP-3)suppresses HCC cell proliferation in both IGF-dependent and independent manners.The present study is to investigate whether treatment with exogenous IGFBP-3 inhibits bF GF and PDGF production and the cell proliferation of HCC cells.METHODS Cell Counting Kit 8 assay were designed to detect HCC cell proliferation,transcription factor early growth response-1(EGR1)involving in IGFBP-3 regulation of b FGF and PDGF were detected by RT-PCR and Western blot assays.Western blot assay was adopted to detect the IGFBP-3 regulating insulin-like growth factor 1 receptor(IGF-1R)signaling pathway.RESULTS The present study demonstrates that IGFBP-3 suppressed IGF-1-induced b FGF and PDGF expression while it does not affect their expression in the absence of IGF-1.To delineate the underlying mechanism,Western-blot and RT-PCR assays confirmed that the transcription factor early growth response protein 1(EGR1)is involved in IGFBP-3 regulation of b FGF and PDGF.IGFBP-3 inhibition of type 1 insulin-like growth factor receptor(IGF1R),ERK and AKT activation is IGF-1-dependent.Furthermore,transient transfection with constitutively activated AKT or MEK partially blocks the IGFBP-3 inhibition of EGR1,b FGF and PDGF expression.CONCLUSION In conclusion,these findings suggest that IGFBP-3suppresses transcription of EGR1 and its target genes b FGF and PDGF through inhibiting IGF-1-dependent ERK and AKT activation.It demonstrates the importance of IGFBP-3 in the regulation of HCC cell proliferation,suggesting that IGFBP-3 could be a target for the treatment of HCC.展开更多
Aim In diabetic patients, metformin appears to provide cardiovascular protection that cannot be attribu- ted only to its antihyperglycemic effects. Metformin is also known as the AMP-activated protein kinase （AMPK） ...Aim In diabetic patients, metformin appears to provide cardiovascular protection that cannot be attribu- ted only to its antihyperglycemic effects. Metformin is also known as the AMP-activated protein kinase （AMPK） ac- tivator. Our previous study suggested that metformin inhibits transforming growth factor-β1 （TGF-β1） production in a mouse heart failure model of pressure overload. TGF-β1 is a key factor in cardiac fibrosis and is usually induced by Angiotensin Ⅱ （Ang Ⅱ ） in the pressure overload mouse models. This study investigated the effect of metformin on cardiac fibrosis and TGF-β production induced by AngII and the underlying mechanisms. Methods C57/BL6 wild-type and AMPKα2 knockout mice were used. AngII （3 mg · kg-1 · d-1） was infused subcutaneously into mice for 7 days. Adult mouse cardiac fibroblasts were isolated and treated with AngII （ 1 μmol · L-1） and/or met- formin （1 mmol · L-l）. Results In C57/BL6 mice, metformin inhibits AngII-induced cardiac fibrosis. In cardi-ac fibroblasts, metformin inhibits TGF-β1 expression and production induced by AngII. AMPK inhibitor, com- pound C, reversed the effects of metformin. In vivo, AMPKα2 deficiency further increases AngII-induced TGF-β1 production. In cardiac fibroblasts, metformin inhibited AngII induced hepatocyte nuclear factor4 （HNF4ot protein level increase and HNF4α binding with TGF-β1 promoter using chromatin immunoprecipitation assay. In vivo, AMPKα2 deficiency further increased AngII-induced HNF4α protein level. Using HNF4α adenovirus, overexpress- ing HNF4α led to a 1.5-fold increase in TGF-β1 mRNA expression. HNF4a siRNA blocked AngII induced TGF- β1 production. Luciferase reporter with deleted HNF4a binding sites showed decreased TGFbl transcriptional activ- ity induced by AngII. In AMPK or2-/- heart, the inhibition of metformin on HNF4a protein was attenuated. Con- clusion Metformin inhibits AngII induced cardiac fibrosis and TGF-β1 production through AMPK activation. The underlying mechanism is that AMPK activation inhibits AngII induced HNF4α and then decreases TGF-β1 expres- sion.展开更多
目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD...目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD同源物3(Smad homolog 3,SMAD3)通路在调控病理性心肌纤维化的作用。方法:建立小鼠心脏纤维化模型,分别于模型组和假手术组中检测E4BP4的表达差异。分离和培养原代心脏成纤维细胞,血管紧张素Ⅱ(angiotensin Ⅱ,Ang Ⅱ)刺激增殖活化,分别转染E4BP4过表达质粒(Ang Ⅱ+E4BP4组)、E4BP4干扰质粒(Ang Ⅱ+siE4BP4组)、Ang Ⅱ组和未经Ang Ⅱ处理的对照组。免疫荧光检测α-肌动蛋白(α-smooth muscle actin,α-SMA)荧光强度,细胞增殖检测试剂盒测定细胞活力,聚合酶链式反应检测E4BP4、α-SMA、Ⅰ型胶原蛋白(collagen type Ⅰ,Collagen Ⅰ)和Ⅲ型胶原蛋白(collagen type Ⅲ,Collagen Ⅲ)的表达,蛋白质印迹检测TGF-β1、AMPK和SMAD3的蛋白表达。结果:与假手术组比较,模型组心肌纤维化程度(38.46±1.21 vs. 3.39±0.39,t=-78.564,P=0.000)、E4BP4蛋白表达量(0.96±0.03 vs. 0.75±0.03,t=-11.480,P=0.000)均明显增加。体外实验发现,与Ang Ⅱ+E4BP4组比较,Ang Ⅱ+siE4BP4组在平均荧光强度(0.05±0.01 vs. 0.42±0.03,F=677.591,P=0.000)、细胞活力(91.30±2.39vs.123.74±2.60,F=132.696,P=0.000)、α-SMA(1.26±0.09vs.3.59±0.86,F=52.274,P=0.000)、Collagen Ⅰ(1.16±0.11vs.3.79±0.89,F=55.336,P=0.000)、Collagen Ⅲ(1.23±0.13 vs. 2.92±0.36,F=119.929,P=0.000)、TGF-β1(0.66±0.04 vs. 0.96±0.02,F=142.954,P=0.000)和p-SMAD3/SMAD3(0.81±0.03 vs. 1.37±0.02,F=739.609,P=0.000)的水平明显降低,而p-AMPK/AMPK的表达量在Ang Ⅱ+siE4BP4组明显高于Ang Ⅱ+E4BP4组(0.89±0.01 vs. 0.58±0.02,F=284.541,P=0.000)。结论:E4BP4是纤维化调控的关键因子,抑制其表达可通过激活AMPK进而抑制TGF-β1/SMAD3通路发挥抗纤维化作用。展开更多
目的探讨孕妇血清胰岛素样生长因子1(insulin like growth factor 1,IGF-1)、IGF-2、IGF结合蛋白3(IGF binding protein 3,IGFBP-3)与正常胎儿生长的关系。方法选择2010年1月至2011年5月于上海市浦东新区人民医院产前检查并分娩正常体...目的探讨孕妇血清胰岛素样生长因子1(insulin like growth factor 1,IGF-1)、IGF-2、IGF结合蛋白3(IGF binding protein 3,IGFBP-3)与正常胎儿生长的关系。方法选择2010年1月至2011年5月于上海市浦东新区人民医院产前检查并分娩正常体重儿的初产妇66例,分为妊娠16～18周、妊娠26～28周、妊娠37～40周3个阶段进行纵向观察,放射免疫法测定孕妇各阶段血清中IGF-1、IGF-2、IGFBP-3水平并进行对比分析。结果孕期母血IGF-1水平随着孕周增加明显上升,其中IGF-1水平在妊娠37～40周高于妊娠26～28周,妊娠26～28周高于妊娠16～18周,差异均有显著统计学意义(P均<0.01)。孕期母血IGF-2水平随孕周增加无明显改变,妊娠3阶段差异无统计学意义(P>0.05)。母血IGFBP-3水平妊娠37～40周高于妊娠26～28周及妊娠16～18周期,差异有统计学意义(P<0.05),而妊娠26～28周与妊娠16～18周无显著差异。妊娠16～18周、26～28周和37～40周3阶段母血IGF-1、IGF-2、IGFBP-3水平与正常新生儿出生体重无显著相关性。结论孕妇血清IGF-1、IGFBP-3水平与正常胎儿生长密切相关,IGF-1可作为临床评价不同阶段正常胎儿生长的指标,而IGFBP-3更多地反映了妊娠中晚期正常胎儿的生长。展开更多
目的评估GH/IGF-1轴与幼龄脑瘫儿童粗大运动功能与认知发育的关系。方法纳入2012年1月至2014年12月新桥医院儿科住院的1-4岁脑瘫儿童71例作为脑瘫组,按体格发育落后与否划分为脑瘫伴发育迟滞组（cerebral palsy with retardation,CP-R...目的评估GH/IGF-1轴与幼龄脑瘫儿童粗大运动功能与认知发育的关系。方法纳入2012年1月至2014年12月新桥医院儿科住院的1-4岁脑瘫儿童71例作为脑瘫组,按体格发育落后与否划分为脑瘫伴发育迟滞组（cerebral palsy with retardation,CP-R）50例及脑瘫发育正常组（cerebral palsy with normal growth,CP-N）21例;按粗大运动功能分类系统（gross motor function classification system,GMFCS）划分为Ⅰ-Ⅱ级组20例（CP-GMFCSⅠ-Ⅱ）,Ⅲ-Ⅴ级组51例（CP-GMFCSⅢ-Ⅴ）;按Bayley评分划分智力发育指数（mental development index,MDI）≥70组15例（CP-MDI≥70）,MDI〈70组56例（CP-MDI〈70）。健康对照组为同期体检的健康儿童15例。观察上述儿童的血浆GH基础值及激发值、胰岛素样生长因子-1（insulin-like growth factorⅠ,IGF-1）、类胰岛素生长因子结合蛋白3（insulin-like growth factor-binding protein 3,IGFBP-3）水平作对照研究。结果 1CP-R组较CP-N组GH峰值显著降低,上述2组均较健康对照组GH峰值和IGF-1值显著降低（P〈0.05）。2CP-GMFCSⅠ-Ⅱ组和CP-GMFCSⅢ-Ⅴ组较健康对照组GH峰值和IGF-1值显著降低,CP-GMFCSⅢ-Ⅴ组较CPGMFCSⅠ-Ⅱ组GH峰值和IGF-1值显著降低（P〈0.05）。3CP-MDI〈70组和CP-MDI≥70组较健康对照组GH峰值显著降低（P〈0.05）;CP-MDI〈70组较CP-MDI≥70组和健康对照组IGF-1值显著降低（P〈0.05）。结论脑瘫伴体格发育迟缓、重度粗大运动功能障碍及明显MDI指数落后的儿童存在GH/IGF-1轴受损,提示GH、IGF-1低下可能是脑瘫儿童运动伴认知水平低下的原因之一。展开更多
基金supported by National Natural Science Foundation of China(81502123 and81330081)Natural Science Foundation of Anhui Province(1308085QH130)Anhui Province Nature Science Foundation in University(KJ2014A119)
文摘OBJECTIVE Basic fibroblast growth factor(b FGF)and platelet-derived growth factor(PDGF)produced by hepatocellular carcinoma(HCC)cells are responsible for the cell growth.Accumulating evidence shows that insulin-like growth factor-binding protein-3(IGFBP-3)suppresses HCC cell proliferation in both IGF-dependent and independent manners.The present study is to investigate whether treatment with exogenous IGFBP-3 inhibits bF GF and PDGF production and the cell proliferation of HCC cells.METHODS Cell Counting Kit 8 assay were designed to detect HCC cell proliferation,transcription factor early growth response-1(EGR1)involving in IGFBP-3 regulation of b FGF and PDGF were detected by RT-PCR and Western blot assays.Western blot assay was adopted to detect the IGFBP-3 regulating insulin-like growth factor 1 receptor(IGF-1R)signaling pathway.RESULTS The present study demonstrates that IGFBP-3 suppressed IGF-1-induced b FGF and PDGF expression while it does not affect their expression in the absence of IGF-1.To delineate the underlying mechanism,Western-blot and RT-PCR assays confirmed that the transcription factor early growth response protein 1(EGR1)is involved in IGFBP-3 regulation of b FGF and PDGF.IGFBP-3 inhibition of type 1 insulin-like growth factor receptor(IGF1R),ERK and AKT activation is IGF-1-dependent.Furthermore,transient transfection with constitutively activated AKT or MEK partially blocks the IGFBP-3 inhibition of EGR1,b FGF and PDGF expression.CONCLUSION In conclusion,these findings suggest that IGFBP-3suppresses transcription of EGR1 and its target genes b FGF and PDGF through inhibiting IGF-1-dependent ERK and AKT activation.It demonstrates the importance of IGFBP-3 in the regulation of HCC cell proliferation,suggesting that IGFBP-3 could be a target for the treatment of HCC.
文摘Aim In diabetic patients, metformin appears to provide cardiovascular protection that cannot be attribu- ted only to its antihyperglycemic effects. Metformin is also known as the AMP-activated protein kinase （AMPK） ac- tivator. Our previous study suggested that metformin inhibits transforming growth factor-β1 （TGF-β1） production in a mouse heart failure model of pressure overload. TGF-β1 is a key factor in cardiac fibrosis and is usually induced by Angiotensin Ⅱ （Ang Ⅱ ） in the pressure overload mouse models. This study investigated the effect of metformin on cardiac fibrosis and TGF-β production induced by AngII and the underlying mechanisms. Methods C57/BL6 wild-type and AMPKα2 knockout mice were used. AngII （3 mg · kg-1 · d-1） was infused subcutaneously into mice for 7 days. Adult mouse cardiac fibroblasts were isolated and treated with AngII （ 1 μmol · L-1） and/or met- formin （1 mmol · L-l）. Results In C57/BL6 mice, metformin inhibits AngII-induced cardiac fibrosis. In cardi-ac fibroblasts, metformin inhibits TGF-β1 expression and production induced by AngII. AMPK inhibitor, com- pound C, reversed the effects of metformin. In vivo, AMPKα2 deficiency further increases AngII-induced TGF-β1 production. In cardiac fibroblasts, metformin inhibited AngII induced hepatocyte nuclear factor4 （HNF4ot protein level increase and HNF4α binding with TGF-β1 promoter using chromatin immunoprecipitation assay. In vivo, AMPKα2 deficiency further increased AngII-induced HNF4α protein level. Using HNF4α adenovirus, overexpress- ing HNF4α led to a 1.5-fold increase in TGF-β1 mRNA expression. HNF4a siRNA blocked AngII induced TGF- β1 production. Luciferase reporter with deleted HNF4a binding sites showed decreased TGFbl transcriptional activ- ity induced by AngII. In AMPK or2-/- heart, the inhibition of metformin on HNF4a protein was attenuated. Con- clusion Metformin inhibits AngII induced cardiac fibrosis and TGF-β1 production through AMPK activation. The underlying mechanism is that AMPK activation inhibits AngII induced HNF4α and then decreases TGF-β1 expres- sion.
文摘目的:探讨转录因子腺病毒E4启动子结合蛋白(adenovirus E4 promoter-binding protein,E4BP4)通过腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)-转化生长因子(transforming growth factor,TGF)-β1/SMAD同源物3(Smad homolog 3,SMAD3)通路在调控病理性心肌纤维化的作用。方法:建立小鼠心脏纤维化模型,分别于模型组和假手术组中检测E4BP4的表达差异。分离和培养原代心脏成纤维细胞,血管紧张素Ⅱ(angiotensin Ⅱ,Ang Ⅱ)刺激增殖活化,分别转染E4BP4过表达质粒(Ang Ⅱ+E4BP4组)、E4BP4干扰质粒(Ang Ⅱ+siE4BP4组)、Ang Ⅱ组和未经Ang Ⅱ处理的对照组。免疫荧光检测α-肌动蛋白(α-smooth muscle actin,α-SMA)荧光强度,细胞增殖检测试剂盒测定细胞活力,聚合酶链式反应检测E4BP4、α-SMA、Ⅰ型胶原蛋白(collagen type Ⅰ,Collagen Ⅰ)和Ⅲ型胶原蛋白(collagen type Ⅲ,Collagen Ⅲ)的表达,蛋白质印迹检测TGF-β1、AMPK和SMAD3的蛋白表达。结果:与假手术组比较,模型组心肌纤维化程度(38.46±1.21 vs. 3.39±0.39,t=-78.564,P=0.000)、E4BP4蛋白表达量(0.96±0.03 vs. 0.75±0.03,t=-11.480,P=0.000)均明显增加。体外实验发现,与Ang Ⅱ+E4BP4组比较,Ang Ⅱ+siE4BP4组在平均荧光强度(0.05±0.01 vs. 0.42±0.03,F=677.591,P=0.000)、细胞活力(91.30±2.39vs.123.74±2.60,F=132.696,P=0.000)、α-SMA(1.26±0.09vs.3.59±0.86,F=52.274,P=0.000)、Collagen Ⅰ(1.16±0.11vs.3.79±0.89,F=55.336,P=0.000)、Collagen Ⅲ(1.23±0.13 vs. 2.92±0.36,F=119.929,P=0.000)、TGF-β1(0.66±0.04 vs. 0.96±0.02,F=142.954,P=0.000)和p-SMAD3/SMAD3(0.81±0.03 vs. 1.37±0.02,F=739.609,P=0.000)的水平明显降低,而p-AMPK/AMPK的表达量在Ang Ⅱ+siE4BP4组明显高于Ang Ⅱ+E4BP4组(0.89±0.01 vs. 0.58±0.02,F=284.541,P=0.000)。结论:E4BP4是纤维化调控的关键因子,抑制其表达可通过激活AMPK进而抑制TGF-β1/SMAD3通路发挥抗纤维化作用。
文摘目的探讨孕妇血清胰岛素样生长因子1(insulin like growth factor 1,IGF-1)、IGF-2、IGF结合蛋白3(IGF binding protein 3,IGFBP-3)与正常胎儿生长的关系。方法选择2010年1月至2011年5月于上海市浦东新区人民医院产前检查并分娩正常体重儿的初产妇66例,分为妊娠16～18周、妊娠26～28周、妊娠37～40周3个阶段进行纵向观察,放射免疫法测定孕妇各阶段血清中IGF-1、IGF-2、IGFBP-3水平并进行对比分析。结果孕期母血IGF-1水平随着孕周增加明显上升,其中IGF-1水平在妊娠37～40周高于妊娠26～28周,妊娠26～28周高于妊娠16～18周,差异均有显著统计学意义(P均<0.01)。孕期母血IGF-2水平随孕周增加无明显改变,妊娠3阶段差异无统计学意义(P>0.05)。母血IGFBP-3水平妊娠37～40周高于妊娠26～28周及妊娠16～18周期,差异有统计学意义(P<0.05),而妊娠26～28周与妊娠16～18周无显著差异。妊娠16～18周、26～28周和37～40周3阶段母血IGF-1、IGF-2、IGFBP-3水平与正常新生儿出生体重无显著相关性。结论孕妇血清IGF-1、IGFBP-3水平与正常胎儿生长密切相关,IGF-1可作为临床评价不同阶段正常胎儿生长的指标,而IGFBP-3更多地反映了妊娠中晚期正常胎儿的生长。
文摘目的评估GH/IGF-1轴与幼龄脑瘫儿童粗大运动功能与认知发育的关系。方法纳入2012年1月至2014年12月新桥医院儿科住院的1-4岁脑瘫儿童71例作为脑瘫组,按体格发育落后与否划分为脑瘫伴发育迟滞组（cerebral palsy with retardation,CP-R）50例及脑瘫发育正常组（cerebral palsy with normal growth,CP-N）21例;按粗大运动功能分类系统（gross motor function classification system,GMFCS）划分为Ⅰ-Ⅱ级组20例（CP-GMFCSⅠ-Ⅱ）,Ⅲ-Ⅴ级组51例（CP-GMFCSⅢ-Ⅴ）;按Bayley评分划分智力发育指数（mental development index,MDI）≥70组15例（CP-MDI≥70）,MDI〈70组56例（CP-MDI〈70）。健康对照组为同期体检的健康儿童15例。观察上述儿童的血浆GH基础值及激发值、胰岛素样生长因子-1（insulin-like growth factorⅠ,IGF-1）、类胰岛素生长因子结合蛋白3（insulin-like growth factor-binding protein 3,IGFBP-3）水平作对照研究。结果 1CP-R组较CP-N组GH峰值显著降低,上述2组均较健康对照组GH峰值和IGF-1值显著降低（P〈0.05）。2CP-GMFCSⅠ-Ⅱ组和CP-GMFCSⅢ-Ⅴ组较健康对照组GH峰值和IGF-1值显著降低,CP-GMFCSⅢ-Ⅴ组较CPGMFCSⅠ-Ⅱ组GH峰值和IGF-1值显著降低（P〈0.05）。3CP-MDI〈70组和CP-MDI≥70组较健康对照组GH峰值显著降低（P〈0.05）;CP-MDI〈70组较CP-MDI≥70组和健康对照组IGF-1值显著降低（P〈0.05）。结论脑瘫伴体格发育迟缓、重度粗大运动功能障碍及明显MDI指数落后的儿童存在GH/IGF-1轴受损,提示GH、IGF-1低下可能是脑瘫儿童运动伴认知水平低下的原因之一。
